Neuros Medical Reports the US FDA’s Approval of Altius Direct Electrical Nerve Stimulation System
Shots:
- The US FDA has granted approval to the company’s Altius Direct Electrical Nerve Stimulation System, with its commercialization anticipated in H2’24
- The system was assessed under the QUEST trial that reached its efficacy & safety endpoints, significant & lasting pain reduction as well as reduced opioid use with improved quality of life when compared to active-sham control
- The system helps manage chronic phantom and residual limb pain in adult amputees. It comprises of a nerve cuff electrode (placed around affected nerve) and an implantable pulse generator & uses Neuros' patented technology to inhibit pain signals from damaged nerves
Ref: Neuros Medical | Image: Neuros Medical
Related Post:- Johnson & Johnson Gains the CHMP’s Positive Opinion for Rybrevant (Amivantamab) as a 1L Treatment of NSCLC
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
